Incyte Corporation (NAS: INCY) Stock Analysis & Fundamentals

INCYIncyte Corporation

NAS · US · Healthcare · Biotechnology · incyte.com

116.65USD+1.36%Mkt Cap: 23.30B $P/E: 16.481d ago

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment o…

Headline	Source	Time
Yesterday
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.	Trefis	22h
What to Expect From Incyte's Q2 2026 Earnings Report Incyte is scheduled to release its second-quarter results later this month, with analysts projecting a double-digit increase in its bottom line figure.	Barchart	1d
This week
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings? Incyte has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 8.6% to $114.25 per share while the index has gained 8.2%.	StockStory	2d
Sector Update: Healthcare Stocks Advance Late Afternoon Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and	MT Newswires	Jul 13
Own Regeneron For Biotech Growth? Incyte Is Making Its Case. For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.	Trefis	Jul 13
Incyte (INCY) Could Be 8% Overvalued As Latarcibart Moves Into Phase 3	Simply Wall St.	Jul 13
How Investors May Respond To Incyte (INCY) Latarcibart Data In Von Willebrand Disease Prophylaxis	Simply Wall St.	Jul 13
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder	Benzinga	Jul 13
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks	StockStory	Jul 13
Older
2 Fast-Growing Pharmaceutical Stocks to Buy Now	Motley Fool	Jul 9
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside	Trefis	Jul 8
Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion	FX Empire	Jul 3
1 Mid-Cap Stock to Research Further and 2 We Avoid	StockStory	Jul 3
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales	Insider Monkey	Jul 1
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura	Zacks	Jun 29
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?	Zacks	Jun 29
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down	StockStory	Jun 29
Incyte (INCY) Stock After 66% One-Year Rally Is The Market Too Optimistic Now	Simply Wall St.	Jun 27
Incyte (INCY) Wins EU Backing For Opzelura As Pipeline Data Builds Across Four Drugs	Simply Wall St.	Jun 27
Lilly, J&J and AbbVie Hit New Highs	GuruFocus.com	Jun 26
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks	Barchart	Jun 22
2 Growth Stocks to Add to Your Roster and 1 We Avoid	StockStory	Jun 22
Here Are Monday’s Best Wall Street Analyst Research Calls: Accenture, Apple, Boyd Gaming, BWX Technologies, Conoco-Phillips, Estee Lauder, Hut 8, Incyte, SpaceX, and More	24/7 Wall St.	Jun 22
Incyte Stock: Is INCY Outperforming the Healthcare Sector?	Barchart	Jun 22
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)	Zacks	Jun 17
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)	Zacks	Jun 16
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review	Zacks	Jun 15
Verizon Upgraded, Oracle Downgraded: Updated Rankings on Top Blue-Chip Stocks	InvestorPlace	Jun 15
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity	Simply Wall St.	Jun 12
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates	Exec Edge	Jun 11
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings	Investor's Business Daily	Jun 11
Why Incyte (INCY) Stock Is Up Today	StockStory	Jun 10
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?	Zacks	Jun 10
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges	StockStory	Jun 10
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B	Zacks	Jun 9
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results	Barchart	Jun 9
Sector Update: Healthcare Stocks Decline Late Afternoon	MT Newswires	Jun 8
Incyte To Acquire Vega Therapeutics For Up To $2 Billion	MT Newswires	Jun 8
Incyte to Buy Vega Therapeutics For Up to $2 Billion	The Wall Street Journal	Jun 8
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles	Motley Fool	Jun 8
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound?	Zacks	Jun 5
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)?	Simply Wall St.	Jun 5
Centene, Deckers and 14 Other ‘Dividend Hopefuls’	Barrons.com	Jun 2
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?	Zacks	May 29
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside	Investing.com	May 28
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?	Zacks	May 28
3 Profitable Stocks for Long-Term Investors	StockStory	May 28
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out	MarketBeat	May 25
How Incyte’s AI-Powered R&D Partnerships At Incyte (INCY) Has Changed Its Investment Story	Simply Wall St.	May 22
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build	MarketBeat	May 18

Industry Peers